Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

870295P

Avanti

DSPE-RGD

Avanti Research™ - A Croda Brand 870295P, powder

Synonym(s):

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-(cysarginylglycylaspartate-maleimidomethyl)cyclohexane-carboxamide] (sodium salt)

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C68H120N9Na2O18PS
CAS Number:
2260795-79-5
Molecular Weight:
1460.75
UNSPSC Code:
12352211
NACRES:
NA.25

form

powder

packaging

pkg of 1 × 1 mg (870295P-1mg)

manufacturer/tradename

Avanti Research™ - A Croda Brand 870295P

application(s)

advanced drug delivery

shipped in

dry ice

storage temp.

−20°C

SMILES string

[H][C@@](COP([O-])(OCCNC(C1CCC(CN2C(CC(SC[C@@H](C([O-])=O)NC([C@H](CC([O-])=O)NC(CNC([C@@H]([NH3+])CCCNC(N)=N)=O)=O)=O)C2=O)=O)CC1)=O)=O)(OC(CCCCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCCCC)=O.[Na+].[Na+]

Biochem/physiol Actions

Arginine-glycine-aspartic acid (RGD) modified liposomes show potential for cancer research.

Packaging

5 mL Amber Glass Screw Cap Vial (870295P-1mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Storage Class

11 - Combustible Solids

flash_point_f

No data available

flash_point_c

No data available

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Cheng-Wei Chen et al.
International journal of nanomedicine, 6, 2567-2580 (2011-12-01)
Human retinal pigment epithelial cells are promising target sites for small interfering RNA (siRNA) that might be used for the prevention and/or treatment of choroidal neovascularization by inhibiting the expression of angiogenic factor; for example, by downregulating expression of the
Yunjie Cao et al.
International journal of clinical and experimental medicine, 8(8), 12182-12191 (2015-11-10)
In this study, we report an active targeting liposomal formulation directed by a novel peptide (RGD) that specifically binds to the integrins receptors overexpressed on prostatic cancer cells. The objectives of this study were to evaluate the in vitro and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service